Case Reports

Sertraline-induced Hemichorea

Emilia M. Gatto 1*, Victoria Aldinio 1, Virginia Parisi 1, Gabriel Persi 1, Gustavo Da Prat 1, Maria Bres Bullrich 1, Pilar Sanchez 1 & Galeno Rojas 1

1 Department of Neurology, Sanatorio de la Trinidad Mitre, Buenos Aires, Argentina

Abstract

Background: Hemichorea–hemiballism is a syndrome secondary to different etiologies. Drug-induced hemichorea is a rare syndrome related to selective serotonin reuptake inhibitors. To the best of our knowledge, no previous cases of hemichorea associated with sertraline have been reported.

Case Report: A 65-year-old female noticed hemichorea 1 week after initiation of sertraline. After extensive investigations, other causes of hemichorea were excluded. Hemichorea remitted after sertraline withdrawal.

Discussion: In our patient, temporal association and the negative clinical assessment supported a diagnosis of likely drug-induced involuntary movement. We hypothesized that enhanced serotonergic transmission in the ventral tegmental area or nigrostriatum may be involved in sertraline-induced hemichorea.

Keywords: Hemichorea, selective serotonin reuptake inhibitors, sertraline, chorea, sertraline, hemichorea

Citation: Gatto EM, Aldinio V, Parisi V, Persi G, Da Prat G, Bullrich MB et al. Sertraline-induced hemichorea. Tremor Other Hyperkinet Mov. 2017; 7. doi: 10.7916/D8XK999F

Introduction

Hemichorea–hemiballism is a spectrum of involuntary, non-patterned movement involving one side of the body. It usually results from a lesion in the contralateral basal ganglia structure, but it is also a well-recognized complication of several conditions, including non-ketotic hyperglycemia and polycythemia vera.1

Although induced parkinsonisms and other hyperkinetic movement disorders are repeatedly reported with selective serotonin reuptake inhibitors (SSRIs),2,3 drug-induced hemichorea has rarely been reported4–9 (Table 1). Herein we report a case of hemichorea induced by sertraline. To the best of our knowledge, no previous cases of sertraline-induced hemichorea have been reported in the literature.

Case report

A 65-year-old right-handed Argentinean female was diagnosed with depression and was started on sertraline 50 mg per day. One week later, she developed involuntary movements involving the left upper and lower limbs.

Twenty-four hours later she was admitted into our institution. Physical examination revealed hemichorea on the left side, but the rest of the neurological and clinical examination, including the Mini Mental Status Examination, was unremarkable.

The patient’s past medical history included smoking (more than 40 cigarettes/day), hiatus hernia, and irritable bowel syndrome. She had no other significant disorders involving the central, peripheral, or autonomic nervous systems. Her family history was non-contributory and no additional medications were taken in the previous 6 months, even for irritable bowel syndrome.

A 1.5 Tesla brain magnetic resonance imaging scan including diffusion-weighted images and magnetic resonance angiography (MRA) was performed 48 hours after the initial symptoms, and no acute lesions or relevant abnormalities were identified (Figure 1). Routine blood tests demonstrated no abnormalities in the full blood count (hemoglobin, 13.2 g/dL; hematocrit, 39.20%) and liver or renal function. Thyroid function, blood glucose, calcium, magnesium, phosphate, serum ceruloplasmin, vitamin D, and parathyroid hormone levels were all normal.

Serum carcinoembryonic antigen, cancer antigen (CA) 15.3, CA 19.9, CA 125, paraneoplastic antibodies (anti-Yo, anti-Hu, anti-Ri), p-Antinuclear and anticytoplasmic antibodies (ANCA) and c-ANCA, anti-transglutaminase, anti-gliadin, and anti-endomysium antibodies, anti-nuclear antibody,
anti-cardiolipin antibody, and HIV serology were negative. To exclude other systemic causes, chest, abdominal, and pelvic computed tomography (CT) scans were performed, which were normal. Carotid ultrasound, echocardiogram, and upper and lower endoscopy were normal.

Cerebrospinal fluid analysis was unremarkable, and onconeural antibodies were negative (anti-Yo, anti-Hu, anti-Ri, anti-N-methyl-D-aspartic acid receptor, anti-Antiglutamate receptor (AMPA subtype1), anti-Antiglutamate receptor (AMPA subtype2), anti-Contactin associated protein 2 (CASPR2), anti-Leucine rich glioma inactivated 1 (LGI 1), gamma-aminobutyric acid B-receptor (GABAB-R), collapsin response mediator protein 5 (CRMP5)). As no other etiologic agents were identified, sertraline was discontinued and the involuntary movements gradually disappeared over 7 days.

The patient was diagnosed with a probable sertraline drug-induced hemichorea. See video, segment 1: basal examination, segment 2: evaluation one month after initial presentation and sertraline withdrawal.
**Discussion**

We present a patient with hemichorea related to sertraline therapy. Sertraline is a SSRI, commonly used in depression.\textsuperscript{10} According to the pharmaco-epidemiological data by the US Food and Drug Administration, only 10\% of all SSRI-induced movement disorders have been reported to be secondary to sertraline,\textsuperscript{11} particularly in those cases with concomitant medications.\textsuperscript{11,12}

The most common movement disorders induced by sertraline included tremor, dystonia, and akathisia.\textsuperscript{12} However, to the best of our knowledge, no previous chorea or hemichorea cases associated with sertraline have been previously reported.

The mechanism by which SSRI could induce movement disorders remains to be elucidated.\textsuperscript{13} Two possible mechanisms have been proposed. The first suggested that sertraline is able not only to inhibit serotonin reuptake but also to exert a mild dopaminergic inhibition in the ventral tegmental area and nigrostriatal pathway.\textsuperscript{14} The second hypothesis proposed a genetic mechanism involving serotonin or dopamine receptor polymorphisms or cytochrome P450 phenotypes.\textsuperscript{15}

These two hypotheses may explain the usually bilateral acute or tardive symptoms; however, it remains to be elucidated why hemichorea rather than generalized chorea occurred in this case.

Several concomitant and previous conditions could contribute to increase the susceptibility for developing hemichorea. In our patient we ruled out chorea gravidarum, post-streptococcal chorea, autoimmune-mediated hemichorea, polycythemia vera, and vascular and structural causes, among others.\textsuperscript{7}

While in this case a personal history of smoking could be observed as a risk factor for hemichorea development, in the literature only one case of smoking was reported as a worsening and non-primary causal factor in a 65-year-old hypertensive male with a right putamen hemorrhage.\textsuperscript{16} In our patient, smoking did not seem to be involved in the pathogenesis of the hemichorea. Therefore, the acute appearance of hemichorea and the recent administration of sertraline, after excluding other possible causes of acquired hemichorea, suggest a probable drug-induced mechanism.

Although the extended use of sertraline revealed a safe profile in daily doses ranging from 50 to 200 mg, it is important to keep in mind that this drug may induce hemichorea, albeit very rarely.

**Acknowledgments**

The authors would like to thank the patient for her participation and collaboration.

**References**

1. Ching Lee P, Chin Kek P, Wah EK, Soh A. Hyperglycemia associated hemichorea-hemiballism: the spectrum of clinical presentation. *Intern Med* 2015; 54:1881–1884. doi: 10.2169/internalmedicine.54.4289

2. Schillevoort I, van Puijlenbroek EP, de Boer A, Roos RA, Jansen PA, Leufkens HG. Extrapyramidal syndromes associated with selective serotonin reuptake inhibitors: a case-control study using spontaneous reports. *Int Clin Psychopharmacol* 2002;17:75–79. doi: 10.1097/00004850-200203000-00006

3. Arai M. Parkinsonism associated with a serotonin and noradrenergic reuptake inhibitor, milnacipran. *J Neurol Neurosurg Psychiatry* 2003;74:137–138. doi: 10.1136/jnnp.74.1.137

4. Borges LG, Bonakdelpour B. Memantine-induced chorea and dystonia. *Pract Neurol* 2017;17:133–134. doi: 10.1136/practneurol-2016-001470

5. Watari T, Tokuda Y. Drug-induced hemichorea. *BMJ Case Rep* 2015 May 20; 2015. pii: bcr2014208872. doi: 10.1136/bcr-2014-208872

6. Sharmila V, Babu TA. Oral contraceptive pills induced hemichorea in an adolescent female with polycystic ovarian disease. *Indian J Pharmocol* 2015;47:232–233. doi: 10.4103/0253-7613.153440

7. Lee HC, Hwang SH, Kang SY. Levosulpiride associated hemichorea. *Yonsei Med J* 2016;57:803–805. doi: 10.3349/ymj.2016.57.3.803

8. Lai MH, Wang TY, Chang CC, Tsai KC, Chang ST. Hemichorea associated with gabapentin therapy with hyperfusion in contralateral basal ganglion – a case of a paraplegic patient with neuropathic pain. *J Clin Pharm Ther* 2008;33:38–38. doi: 10.1111/j.1365-2710.2008.00882.x

9. Srinivasan S, Lok AW. Valproate-induced reversible hemichorea. *Mov Disord* 2010;25:1511–1512. doi: 10.1002/mds.23119

10. Cipriani A, La Ferla T, Furukawa TA, Signoretti A, Nakagawa A, Churchill R, et al. Sertraline versus other antidepressive agents for depression. *Cochrane Database Syst Rev* 2009;CD006117. doi: 10.1002/14651858.CD006117

11. Madhusoodanan S, Alexenko L, Sanders R, Brenner R. Extrapyramidal symptoms associated with antidepressants – a review of the literature and an analysis of spontaneous reports. *Am J Psychiatry* 2010;22:148–156.

12. Schillevoort I, van Puijlenbroek EP, de Boer A, Roos RC, Jansend PAF, Leufkens HG. Extrapyramidal syndromes associated with selective serotonin reuptake inhibitors: a case-control study using spontaneous reports. *Int Clin Psychopharmacol* 2002;17:75–79. doi: 10.1097/00004850-200203000-00006

13. Gill HS, DeVane CL, Risch SC. Extrapyramidal symptoms associated with cyclic antidepressant treatment: a review of the literature and consolidating hypotheses. *J Clin Psychopharmacol* 1997;17:377–389. doi: 10.1097/00004714-199710000-00007

14. Wang LF, Huang JW, Shan SY, Ding JH, Lai JB, Xu Y, et al. Possible sertraline-induced extrapyramidal adverse effects in an adolescent. *Neuropsychiatr Dis Treat* 2016;12:1127–1129. doi: 10.2147/NDT.S106562

15. Hedenmalm K, Güzey C, Dahl ML, Yue QY, Spigset O. Risk factors for extrapyramidal symptoms during treatment with selective serotonin reuptake inhibitors, including cytochrome P-450 enzyme, and serotonin and dopamine transporter and receptor polymorphisms. *J Clin Psychopharmacol* 2006;26:192–197. doi: 10.1097/01.jcp.0000203200.96205.34

16. Mochizuki H, Miwa H, Imai H, Muzuno Y. [Hemiballism-hemichorea caused by a putaminal hemorrhage with worsening after smoking—a case report]. *Rinsho Shinkeigaku* 1993;33:562–564.